Continuous Professional Education Programme for Registered Nurses and Midwives to Administer Menjugate Vaccine

Under the Medicine Protocol to Students in Second Level Schools (or age equivalent) through a Schools Immunisation Programme

Changing practice to support service delivery
Medicine Protocol

• This Medicine Protocol is a specific written instruction for the administration of Menjugate Vaccine to Students who may not be individually identified before presentation for treatment.
Clinical Criteria

Active immunisation against and prevention of Meningococcal Group C (Men C) disease, where stocks still available locally
Circumstances in which the Medicine Protocol applies

• Meningococcal C immunisation programme was delivered annually until Sept 2019 by the Health Service Executive (HSE) mainly via School Immunisation Programme.

• Menjugate should now only be used for those older than first year requesting Meningococcal vaccination in exceptional circumstances, if the area still has stocks of Men C vaccine. Otherwise Men ACWY should be used.
Inclusion Criteria for Menjugate Vaccine

For 2019/2020 Menjugate may only be given, to students who are outside the First year cohort group, but are still in school, who missed the Menjugate vaccine in first year due to medical reasons/exceptional circumstances and whose parents/legal guardians now request Meningococcal vaccine AND where the area still has stocks of Menjugate

Otherwise Men ACWY vaccine should be used

Students with valid consent.
Exclusion Criteria for Menjugate Vaccine

• Any student in First year of second level school (Men ACWY vaccine should be given instead)

• Any Student who has had an anaphylactic or hypersensitivity reaction to a previous dose of Menjugate or any of the vaccine components or any vaccine containing the same substances

• Acute febrile illness: The presence of a minor infection such as a mild upper respiratory infection or low grade fever is **not** a contraindication to immunisation.
Exclusion criteria cont....

• Students with a contraindication to intramuscular injection (haematological disorder/coagulation disorder e.g. haemophilia, severe thrombocytopenia).

• Students who are immunocompromised either due to disease or treatment.
Menjugate Vaccine: Product Information

Details of the most current and update information of the SmPC and other data is available on the website

https://www.hpra.ie
Possible Side Effects

• The following possible side effect are ranked under the headings.
  • Very Common adverse events in adolescents/adults (these may occur in more than 1 in 10 doses of the vaccine)
  • Injection site reactions (redness, swelling and tenderness)
  • Headache (adolescents)
  • Myalgia and arthralgia
  • Malaise
  • Nausea (adults)

• Common adverse events in all age groups (these may occur in more than 1 in 100 doses and less than 1 in 10 doses of the vaccine)
  • Fever $\geq 38^\circ\text{C}$

• For a full list of side effects refer to [https://www.hpra.ie](https://www.hpra.ie)
Menjugate Constituents

Meningococcal Group C vaccine
– One dose (0.5 ml of the reconstituted vaccine) contains:
– *Neisseria meningitides* group C (strain C11) oligosaccharide 10 micrograms Conjugated to *Corynebacterium diphtheria* CRM – 197 protein adsorbed on aluminium hydroxide 12.5 to 25.0 micrograms 0.3 to 0.4 mg Al\(^{3+}\)
List of excipients

Each 0.5ml dose contains
• MenC-CRM197 Conjugate
• Mannitol
• Sodium dihydrogen phosphate monohydrate
• Disodium phosphate – heptahydrate
Syringe containing aluminium hydroxide
• Sodium chloride
• Water for injections
Nature and contents of container

Menjugate is presented as single packs prefilled with 2 needles 23G x 25mm should be used. 25G x 16mm needle is not recommended.